Recludix Pharma Bolsters Scientific Advisory Board with Acclaimed Leaders in the Fields of Rheumatology, Dermatology and JAK/STAT Biology
Kharabi led development of CD19 CAR-T therapy TECARTUS®; brings extensive cell and gene therapy expertise to guide 3T’s bispecific T-cell engager programs into the clinic
Proceeds will fund a global pivotal trial of lead product candidate, ELA026, as a frontline treatment for secondary hemophagocytic lymphohistiocytosis (sHLH)
The SURPASS study is enrolling patients at research sites across the U.S. and Europe
ELA026 has demonstrated promising potential as a frontline treatment for patients with sHLH, a hyperinflammatory disease with high mortality and significant unmet medical need
Proceeds to support continued clinical advancement of lead program, VGA039, a first-in-class antibody targeting protein S for the treatment of bleeding disorders, starting with von Willebrand disease (VWD)
ROC-101 exhibits favorable pharmacokinetics for once-daily dosing
Funding to advance first-in-class pan-ROCK inhibitor through Phase 2a testing in PAH and ILD-PH patients
Warner Biddle describes the trajectory of the field, and how neuro-autoimmune conditions have emerged as Kyverna’s most advanced programs. We discuss Stiff Person Syndrome, myasthenia gravis, MS and more.
NEULARK trial to evaluate NEU-411, a brain-penetrant, potent and selective LRRK2 inhibitor, in people with LRRK2-driven Parkinson’s disease; topline data anticipated in 2027
